Skip to main content
Premium Trial:

Request an Annual Quote

DeCode, Pharmacia Enter Cardiology Research Collaboration

NEW YORK, Jan. 15 - DeCode genetics has launched a pharmacogenomics alliance with Pharmacia in order to probe the genetics of heart disease progression, the company said on Tuesday.

 

The companies hope to isolate genetic markers that can be used to identify patients who will benefit from the cardiovascular drugs that Pharmacia is currently developing. Specifically, under terms of the deal, deCode will use its population data and genetic marker-discovery techniques to identify patients who are predisposed to progress rapidly from early-stage to advanced heart disease.

 

Terms of the deal further call for the Icelandic population genetics company will receive contract fees through Encode, its pharmacogenomics, and CRO subsidiary. Encode may also receive royalties on diagnostic tests or cardiovascular drug sales, if Pharmacia exercises license options.

 

Further financial details were not disclosed.

 

The therapeutic goal of the partnership is to make it possible early on to identify patients who are likely to develop advanced heart disease, and provide preventive treatment, deCode CEO Kari Stefansson said in a statement.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.